Patient characteristics
| . | All patients (N = 78) . | AITL/TFH patients (n = 71) . |
|---|---|---|
| Age median (IQR) | 70 (67-73) | 70 (67-73) |
| Sex | ||
| Female | 41 (53) | 38 (53) |
| Male | 37 (47) | 33 (47) |
| B symptoms | 44/78 (56) | 40/71 (56) |
| Ann Arbor stage | ||
| I-II | 5 (6) | 5 (7) |
| III-IV | 73 (94) | 66 (93) |
| Number of extranodal sites | ||
| 0-1 | 40 (51) | 38 (53) |
| >1 | 38 (49) | 33 (47) |
| ECOG performance status | ||
| 0-1 | 61 (78) | 54 (76) |
| 2 | 17 (22) | 17 (24) |
| Bone marrow involvement | 36/73 (49) | 32/66 (48) |
| Hypergammaglobulinemia | 30/70 (43) | 29/64 (45) |
| Elevated LDH | 42/77 (55) | 39/70 (56) |
| Histology | ||
| AITL | 67 (94) | 67 (86) |
| Nodal PTCL with TFH phenotype | 4 (6) | 4 (5) |
| Other* | 7 (9) | 0 (0) |
| IPI | ||
| 1-3 | 48 (62) | 43 (61) |
| 4-5 | 29 (38) | 27 (39) |
| PIT | ||
| 0-2 | 50 (69) | 45 (69) |
| 3-4 | 22 (31) | 20 (31) |
| SUVmax median (IQR) | 11 (7-18) | 12 (7-18) |
| TMTV median (IQR) | 433 (127-937) | 468 (125-942) |
| . | All patients (N = 78) . | AITL/TFH patients (n = 71) . |
|---|---|---|
| Age median (IQR) | 70 (67-73) | 70 (67-73) |
| Sex | ||
| Female | 41 (53) | 38 (53) |
| Male | 37 (47) | 33 (47) |
| B symptoms | 44/78 (56) | 40/71 (56) |
| Ann Arbor stage | ||
| I-II | 5 (6) | 5 (7) |
| III-IV | 73 (94) | 66 (93) |
| Number of extranodal sites | ||
| 0-1 | 40 (51) | 38 (53) |
| >1 | 38 (49) | 33 (47) |
| ECOG performance status | ||
| 0-1 | 61 (78) | 54 (76) |
| 2 | 17 (22) | 17 (24) |
| Bone marrow involvement | 36/73 (49) | 32/66 (48) |
| Hypergammaglobulinemia | 30/70 (43) | 29/64 (45) |
| Elevated LDH | 42/77 (55) | 39/70 (56) |
| Histology | ||
| AITL | 67 (94) | 67 (86) |
| Nodal PTCL with TFH phenotype | 4 (6) | 4 (5) |
| Other* | 7 (9) | 0 (0) |
| IPI | ||
| 1-3 | 48 (62) | 43 (61) |
| 4-5 | 29 (38) | 27 (39) |
| PIT | ||
| 0-2 | 50 (69) | 45 (69) |
| 3-4 | 22 (31) | 20 (31) |
| SUVmax median (IQR) | 11 (7-18) | 12 (7-18) |
| TMTV median (IQR) | 433 (127-937) | 468 (125-942) |
Data n (%) or n/N (%) except as noted.
IPI, International Prognostic Index43 ; PIT, Prognostic Index for peripheral T-cell lymphoma, unspecified.44
*Other diagnosis consisted of T cells and histiocyte-rich diffuse large B-cell lymphoma (N = 1), PTCL that cannot be classified (N = 3), uncertain diagnosis of tumor (N=1), and no histologic material available for pathologic review (N = 2).